

Long-Term Lamivudine Therapy Reduces the Risk of Late Hepatitis B Infection even in Patients without Advanced

Antiviral Therapy

12, 1295-1304

DOI: [10.1177/135965350701200816](https://doi.org/10.1177/135965350701200816)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Nucleos(t)ide analogues for hepatitis B virus: Strategies for long-term success. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2008, 22, 1081-1092.	1.0	28
2	New paradigms for the treatment of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1182-1192.	1.4	23
3	Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 1067-1077.	1.9	338
4	HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 135, 1192-1199.	0.6	370
5	LB80380: a promising new drug for the treatment of chronic hepatitis B. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1581-1588.	1.9	22
6	Resistance issues in treating chronic hepatitis B. <i>Future Microbiology</i> , 2008, 3, 525-538.	1.0	19
7	Chronic Hepatitis B – New Goals, New Treatment. <i>New England Journal of Medicine</i> , 2008, 359, 2488-2491.	13.9	107
8	Pharmacokinetics of LB80331 and LB80317 following Oral Administration of LB80380, a New Antiviral Agent for Chronic Hepatitis B (CHB), in Healthy Adult Subjects, CHB Patients, and Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1779-1785.	1.4	21
9	Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. <i>Hepatology</i> , 2009, 49, 72-79.	3.6	163
10	Antiviral resistance and hepatitis B therapy. <i>Hepatology</i> , 2009, 49, S174-S184.	3.6	189
11	The saga of entecavir. <i>Hepatology International</i> , 2009, 3, 421-424.	1.9	2
12	Current treatment of chronic HBV infection: An Asian-Pacific perspective. <i>Current Hepatitis Reports</i> , 2009, 8, 154-160.	0.3	2
13	Prevention of hepatocellular carcinoma in hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1352-1357.	1.4	67
14	Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. <i>Liver International</i> , 2009, 29, 100-107.	1.9	181
15	Hepatitis B and C virus-related carcinogenesis. <i>Clinical Microbiology and Infection</i> , 2009, 15, 964-970.	2.8	123
16	Prevention of hepatocellular carcinoma: The holy grail of hepatitis B treatment. <i>Journal of Hepatology</i> , 2009, 50, 854-856.	1.8	1
17	Chronic hepatitis B: who to treat and which choice of treatment?. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 281-291.	2.0	9
18	Monotherapy versus combination therapy for the treatment of chronic hepatitis B. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1655-1666.	1.9	38

#	ARTICLE	IF	CITATIONS
19	Current challenges in viral hepatitis, antimicrobial resistance and the influenza pandemic. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 945-949.	2.0	0
21	Higher pretherapy and significant decrease during the first 12 months of therapy in serum laminin levels may associate with hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with lamivudine. <i>Clinical and Experimental Medicine</i> , 2010, 10, 245-251.	1.9	2
22	Drug Delivery Systems and Liver Targeting for the Improved Pharmacotherapy of the Hepatitis B Virus (HBV) Infection. <i>Pharmaceutical Research</i> , 2010, 27, 1184-1202.	1.7	25
23	A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. <i>Clinical Therapeutics</i> , 2010, 32, 649-658.	1.1	21
24	Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. <i>Hepatology</i> , 2010, 51, 767-776.	3.6	39
25	Prevention of hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2010, 9, 120-132.	0.6	14
26	Therapy with Nucleos(t)ide Analogues: Current Role in Dialysis Patients. <i>International Journal of Artificial Organs</i> , 2010, 33, 329-338.	0.7	12
27	Mechanism of Entecavir Resistance of Hepatitis B Virus with Viral Breakthrough as Determined by Long-Term Clinical Assessment and Molecular Docking Simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 882-889.	1.4	31
28	How to Overcome Antiviral-Resistant Hepatitis B Virus?. <i>Intervirolgy</i> , 2010, 53, 29-38.	1.2	4
29	Response to Adefovir Depends on Mutation Patterns in Precore Region, Basal Core Promoter and Reverse Transcriptase, and On-Treatment Responses in Lamivudine-Resistant Chronic Hepatitis B Patients. <i>Intervirolgy</i> , 2010, 53, 203-210.	1.2	6
30	Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections. <i>Viruses</i> , 2010, 2, 1279-1305.	1.5	56
31	Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 717-726.	2.0	19
32	Does chemotherapy prevent HBV-related hepatocellular carcinoma? <i>Pros. Digestive and Liver Disease</i> , 2010, 42, S293-S297.	0.4	7
33	A Review of Oral Antiretroviral Therapy for the Treatment of Chronic Hepatitis B. <i>Annals of Pharmacotherapy</i> , 2010, 44, 1271-1286.	0.9	9
34	Hepatocellular carcinoma: a global view. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 448-458.	8.2	1,159
35	Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review. <i>Journal of Hepatology</i> , 2010, 53, 348-356.	1.8	397
36	Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 1079-1092.	2.0	15
37	Epidemiology and Management of Hepatocellular Carcinoma. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 899-919.	1.9	166

#	ARTICLE	IF	CITATIONS
38	Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 64-70.	2.4	216
39	Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version. <i>Digestive Diseases</i> , 2011, 29, 339-364.	0.8	726
40	Hepatitis B: Modern End Points of Treatment and the Specter of Viral Resistance. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 495-505.	1.0	15
42	The Role of Oncogenic Viruses in the Pathogenesis of Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2011, 15, 261-279.	1.0	36
43	Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. <i>Journal of Hepatology</i> , 2011, 55, 522-528.	1.8	33
44	Canadian Patients with Chronic Hepatitis B Cannot Access Appropriate Drug Treatments: A Call for Change. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2011, 25, 538-541.	1.8	2
45	Treatment of chronic hepatitis B: Evolution over two decades. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 138-143.	1.4	143
46	Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2011, 18, 738-744.	1.0	42
47	Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2011, 18, e252-7.	1.0	16
48	Impact of hepatitis B therapy on the long-term outcome of liver disease. <i>Liver International</i> , 2011, 31, 117-121.	1.9	38
49	Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. <i>Current Hepatitis Reports</i> , 2011, 10, 235-243.	0.3	25
50	Long-Term Nucleos(t)ide Analogues Therapy for Adults With Chronic Hepatitis B reduces the Risk of Long-Term Complications: a meta-analysis. <i>Virology Journal</i> , 2011, 8, 72.	1.4	55
51	Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: Outcome at 2 Years. <i>Hepatology</i> , 2011, 53, 1148-1153.	3.6	12
53	The Cost-effectiveness of Screening for Chronic Hepatitis B Infection in the United States. <i>Clinical Infectious Diseases</i> , 2011, 52, 1294-1306.	2.9	74
54	Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2715-2725.	1.3	168
55	Impact of Antiviral Therapy on the Survival of Patients After Major Hepatectomy for Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Archives of Surgery</i> , 2011, 146, 675.	2.3	102
56	Prevention of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection. <i>Oncology</i> , 2011, 81, 41-49.	0.9	42
57	Tenofovir in the treatment of chronic hepatitis B. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 527-544.	0.2	1

#	ARTICLE	IF	CITATIONS
58	Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs. Expert Review of Gastroenterology and Hepatology, 2012, 6, 187-198.	1.4	29
59	Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis. Scientifica, 2012, 2012, 1-22.	0.6	5
60	Outcome of Lamivudine-Resistant Chronic Hepatitis B after up to 5 Years of Combination Therapy with Adefovir. Antiviral Therapy, 2012, 17, 1255-1262.	0.6	18
61	Future Prevention and Treatment of Chronic Hepatitis B Infection. Journal of Clinical Gastroenterology, 2012, 46, 725-734.	1.1	5
62	Chronic HBV infection outside treatment guidelines: is treatment needed?. Antiviral Therapy, 2012, 18, 229-235.	0.6	17
64	Rescue Therapy for Lamivudine-resistant Chronic Hepatitis B: Adefovir Monotherapy, Adefovir Plus Lamivudine or Entecavir Combination Therapy. Internal Medicine, 2012, 51, 1509-1515.	0.3	21
65	7. Cutting Edge of the Treatment for Viral Hepatitis. The Journal of the Japanese Society of Internal Medicine, 2012, 101, 131c-132a.	0.0	0
66	Prevention and management of drug resistant hepatitis B virus infections. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1432-1440.	1.4	12
67	Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 685-696.	1.4	41
68	Causes of and Prevention Strategies for Hepatocellular Carcinoma. Seminars in Oncology, 2012, 39, 374-383.	0.8	49
69	Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients. Virology Journal, 2012, 9, 239.	1.4	18
70	Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. Expert Review of Gastroenterology and Hepatology, 2012, 6, 683-694.	1.4	20
71	Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. Hepatology International, 2012, 6, 696-706.	1.9	7
72	Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. Liver International, 2012, 32, 137-146.	1.9	24
73	A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East. Journal of Viral Hepatitis, 2012, 19, 9-22.	1.0	37
74	Use of RNA interference to modulate liver adenoma development in a murine model transgenic for hepatitis B virus. Gene Therapy, 2012, 19, 25-33.	2.3	10
75	Hepatitis B virus directly promotes collagen I expression of LX-2 cells without infection <i>in vitro</i> . Hepatology Research, 2012, 42, 911-921.	1.8	3
76	Acute-on-chronic liver failure in chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 662-669.	1.4	62

#	ARTICLE	IF	CITATIONS
77	Furin mRNA expression in peripheral blood correlates with chronic hepatitis B virus infection. <i>Hepatology Research</i> , 2013, 43, 208-216.	1.8	6
78	Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B mono-infection. <i>Hepatology International</i> , 2013, 7, 327-334.	1.9	3
79	Are physicians following guidelines? A survey of Hepatitis B management strategies. <i>Hepatology International</i> , 2013, 7, 451-459.	1.9	5
80	Resistance is no Longer a Problem with Entecavir and Tenofovir. <i>Current Hepatitis Reports</i> , 2013, 12, 96-104.	0.3	0
81	Long-term therapy for chronic hepatitis B: Hepatitis B virus DNA suppression leading to cirrhosis reversal. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 912-923.	1.4	40
82	Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. <i>Hepatology</i> , 2013, 58, 923-931.	3.6	88
83	Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. <i>Hepatology</i> , 2013, 57, 399-408.	3.6	183
84	Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment?. <i>Journal of Medical Virology</i> , 2013, 85, 34-42.	2.5	11
85	Increased viral quasispecies evolution in HBeAg seroconverter patients treated with oral nucleoside therapy. <i>Journal of Hepatology</i> , 2013, 58, 217-224.	1.8	28
86	Impact of Therapy on the Long-Term Outcome of Chronic Hepatitis B. <i>Clinics in Liver Disease</i> , 2013, 17, 413-423.	1.0	40
87	Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: A propensity score analysis. <i>Journal of Hepatology</i> , 2013, 58, 427-433.	1.8	124
88	Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. <i>Journal of Hepatology</i> , 2013, 59, 709-716.	1.8	52
89	Impact of therapy on the outcome of chronic hepatitis B. <i>Liver International</i> , 2013, 33, 111-115.	1.9	55
90	Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 11-18.	1.3	15
91	Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. <i>BMJ Open</i> , 2013, 3, e003265.	0.8	30
92	Resolution of adefovir-related nephrotoxicity by adefovir dose reduction in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 710-719.	1.9	18
93	Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2013, 85, 987-995.	2.5	19
94	Efficacy of Lamivudine or Entecavir against Virological Rebound after Achieving HBV DNA Negativity in Chronic Hepatitis B Patients. <i>International Journal of Medical Sciences</i> , 2013, 10, 647-652.	1.1	10

#	ARTICLE	IF	CITATIONS
95	52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B. <i>PLoS ONE</i> , 2013, 8, e54279.	1.1	34
96	Predictability of Liver-Related Seromarkers for the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2013, 8, e61448.	1.1	34
97	Large Variations in Risk of Hepatocellular Carcinoma and Mortality in Treatment Naïve Hepatitis B Patients: Systematic Review with Meta-Analyses. <i>PLoS ONE</i> , 2014, 9, e107177.	1.1	37
98	Current developments in nucleoside/nucleotide analogues for hepatitis B. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 607-622.	1.4	36
99	Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1049-1055.	1.4	6
100	Does suppression of HBV replication by antiviral therapy confer the same benefit as host immune control of HBV?. <i>Gut</i> , 2014, 63, 1833-1834.	6.1	3
101	Impact of HBV therapy on the incidence of hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 139-145.	1.9	31
102	Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. <i>Gut</i> , 2014, 63, 996-1004.	6.1	67
103	Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1485-1493.	1.4	4
104	Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 959-967.	1.0	2
105	Telbivudine Versus Entecavir for Nucleos(t)ide-Naive HBeAg-Positive Chronic Hepatitis B: A Meta-analysis. <i>American Journal of the Medical Sciences</i> , 2014, 347, 131-138.	0.4	11
106	The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1262-1269.	1.9	53
107	JSH Guidelines for the Management of Hepatitis B Virus Infection. <i>Hepatology Research</i> , 2014, 44, 1-58.	1.8	142
108	A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand. <i>BMC Health Services Research</i> , 2014, 14, 170.	0.9	10
109	Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. <i>Gut</i> , 2014, 63, 1943-1950.	6.1	149
110	Application of Coamplification at Lower Denaturation Temperature-PCR Sequencing for Early Detection of Antiviral Drug Resistance Mutations of Hepatitis B Virus. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3209-3215.	1.8	12
111	Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1028-1034.	1.4	58
112	Mortality, Liver Transplantation, and Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B Treated With Entecavir vs Lamivudine. <i>Gastroenterology</i> , 2014, 147, 152-161.	0.6	133

#	ARTICLE	IF	CITATIONS
113	Comparison of the efficacies of entecavir 0.5 and 1.0mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. <i>Journal of Medical Virology</i> , 2015, 87, 999-1007.	2.5	0
114	Outcomes including liver histology after liver transplantation for chronic hepatitis B using oral antiviral therapy alone. <i>Liver Transplantation</i> , 2015, 21, 1504-1510.	1.3	21
115	Hepatocellular carcinoma: From diagnosis to treatment. <i>World Journal of Hepatology</i> , 2015, 7, 1020.	0.8	137
116	Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. <i>World Journal of Hepatology</i> , 2015, 7, 1064.	0.8	46
117	Efficacy of tenofovir disoproxil fumarate therapy in Chinese chronic hepatitis B patients after multiple antiviral failures. <i>Hepatology Research</i> , 2015, 45, E43-52.	1.8	1
118	Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 439-451.	1.0	5
119	Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: Results from a multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 526-532.	1.8	46
120	Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Journal of Hepatology</i> , 2015, 62, 363-370.	1.8	138
121	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. <i>Gut</i> , 2015, 64, 667-672.	6.1	185
122	Reimbursement policies in the Asia-Pacific for chronic hepatitis B. <i>Hepatology International</i> , 2015, 9, 43-51.	1.9	20
123	Prevention of Hepatocellular Carcinoma: Beyond Hepatitis B Vaccination. <i>Seminars in Oncology</i> , 2015, 42, 316-328.	0.8	16
124	Genomic Applications in the Clinical Management of Infectious Diseases. , 2015, , 581-604.		0
125	Improving clinical outcomes of chronic hepatitis B virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 141-154.	1.4	24
127	Monotherapy for hepatitis B infection: a review of treatment options. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1457-1468.	2.0	7
128	Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 199-208.	1.9	51
129	KASL clinical practice guidelines: management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 18-75.	4.5	155
130	Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-11.	0.8	20
131	Treatment for hepatitis B in patients with drug resistance. <i>Annals of Translational Medicine</i> , 2016, 4, 334-334.	0.7	22

#	ARTICLE	IF	CITATIONS
132	Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigenâ€“positive chronic hepatitis B. <i>Hepatology</i> , 2016, 63, 377-387.	3.6	74
133	Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 286-294.	1.1	42
134	Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. <i>Hepatology International</i> , 2016, 10, 574-593.	1.9	18
135	Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and metaâ€“analysis. <i>Hepatology</i> , 2016, 63, 284-306.	3.6	414
136	Bodyâ€“mass index is associated with fibrosis regression during longâ€“term nucleoside analogue therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1071-1079.	1.9	33
137	Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and metaâ€“analysis. <i>Liver International</i> , 2016, 36, 1239-1251.	1.9	114
138	Reduction of chronic hepatitis Bâ€“related hepatocellular carcinoma with antiâ€“viral therapy, including low risk patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 846-855.	1.9	47
139	Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, openâ€“label, multicenter study. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 559-566.	0.8	2
140	Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B. <i>BMC Gastroenterology</i> , 2016, 16, 38.	0.8	14
141	Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. <i>Gut</i> , 2016, 65, 852-860.	6.1	70
142	Hepatitis B: treatment choice and monitoring for response and resistance. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 697-707.	1.4	11
143	Efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis B virus: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 447-456.	0.7	5
144	The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 546-552.	1.4	19
145	Emerging drugs for the treatment of hepatitis B. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 183-193.	1.0	8
146	Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. <i>Journal of Gastroenterology</i> , 2016, 51, 487-495.	2.3	28
147	Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients. <i>Hepatology International</i> , 2016, 10, 320-327.	1.9	15
148	Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. <i>Gut</i> , 2016, 65, 1042-1051.	6.1	76
149	Tenofovir Disoproxil Fumarate Monotherapy is Superior to Entecavir-Adefovir Combination Therapy in Patients with Suboptimal Response to Lamivudine-Adefovir Therapy for Nucleoside-Resistant HBV: A 96-Week Prospective Multicentre Trial. <i>Antiviral Therapy</i> , 2018, 23, 219-227.	0.6	9

#	ARTICLE	IF	CITATIONS
150	New antivirals for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs, 2017, 26, 843-851.	1.9	43
151	Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy. Scandinavian Journal of Gastroenterology, 2017, 52, 1-8.	0.6	10
152	Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years. Hepatology, 2017, 66, 1036-1044.	3.6	89
153	Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study. Journal of Viral Hepatitis, 2017, 24, 12-20.	1.0	21
154	Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation. Transplantation, 2017, 101, 2391-2398.	0.5	6
155	Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B. Medicine (United States), 2017, 96, e8454.	0.4	17
156	Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance. Journal of Viral Hepatitis, 2017, 24, 141-147.	1.0	23
157	Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy. Journal of Medical Virology, 2017, 89, 85-90.	2.5	5
158	Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B. Current Medical Research and Opinion, 2017, 33, 495-504.	0.9	20
159	Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B. Annals of Hepatology, 2017, 16, 358-365.	0.6	6
160	Management of Antiviral Resistance in Chronic Hepatitis B. Gut and Liver, 2017, 11, 189-195.	1.4	39
161	Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels. Annals of Surgery, 2018, 268, 943-954.	2.1	97
162	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. Journal of Hepatology, 2018, 68, 1129-1136.	1.8	88
163	Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2018, 16, 575-583.e2.	2.4	86
164	Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. Journal of Hepatology, 2018, 68, 526-549.	1.8	506
165	Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 262-279.	1.8	160
166	Future Drugs in the Treatment of HBV. , 2018, , 105-117.		0
167	KASL clinical practice guidelines for management of chronic hepatitis B. Clinical and Molecular Hepatology, 2019, 25, 93-159.	4.5	171

#	ARTICLE	IF	CITATIONS
168	Introduction to Acute Exacerbation of Chronic Hepatitis B (AECHB). , 2019, , 1-47.		0
169	Fibrosis evolution in chronic hepatitis B e antigenâ€negative patients across a 10â€year interval. Journal of Viral Hepatitis, 2019, 26, 818-827.	1.0	40
170	Novel developments of hepatitis B: treatment goals, agents and monitoring tools. Expert Review of Clinical Pharmacology, 2019, 12, 109-120.	1.3	29
171	Hepatitis B Virus: Asian Perspective. , 2019, , 99-116.		2
172	Nucleoside analog monotherapy for prophylaxis in Hepatitis B liver transplant patients is safe and efficacious. Hepatology International, 2020, 14, 57-69.	1.9	11
173	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. American Journal of Gastroenterology, 2020, 115, 271-280.	0.2	72
174	Long-Term Traditional Chinese Medicine Combined with NA Antiviral Therapy on Cirrhosis Incidence in Chronic Hepatitis B Patients in the Real-World Setting: A Retrospective Study. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-8.	0.5	6
175	Examining Liver Cancer Patients and a High-Risk Group in a Vulnerable Area: An Experience from the Ulleung Liver Cancer Prevention and Management Project. International Journal of Environmental Research and Public Health, 2020, 17, 7757.	1.2	0
177	Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy. World Journal of Gastroenterology, 2021, 27, 1101-1116.	1.4	7
178	Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance. Hepatology International, 2021, 15, 881-891.	1.9	2
179	Entecavir Monotherapy Prevents Hepatitis B Virus Recurrence After Liver Transplant for Chronic Hepatitis B Patients: A Long-Term Retrospective Study. Transplantation Proceedings, 2021, 53, 1700-1706.	0.3	4
180	Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients. BMC Infectious Diseases, 2021, 21, 912.	1.3	1
181	Controversies in Treating Chronic Hepatitis B virus. Clinics in Liver Disease, 2021, 25, 763-784.	1.0	1
182	Hepatitis B Virus and Hepatitis Delta Virus. , 2015, , 1815-1839.e7.		17
183	Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis. European Journal of Gastroenterology and Hepatology, 2018, 30, 1277-1282.	0.8	2
184	Association of Adjuvant Antiviral Therapy with Risk of Cancer Progression and Deaths in Patients with Hepatitis-B-Virus-Related Hepatocellular Carcinoma following Curative Treatment: A Nationwide Cohort Study. PLoS ONE, 2014, 9, e102051.	1.1	13
185	The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs. Journal of Clinical and Translational Hepatology, 2014, 2, 202-11.	0.7	20
186	Current Trends of Combination Therapy in Chronic Hepatitis B Management in China. Archives of Hepatitis Research, 2015, 1, 001-004.	0.4	1

#	ARTICLE	IF	CITATIONS
187	Guidelines for the management of hepatitis B virus infection. <i>Acta Hepatologica Japonica</i> , 2013, 54, 402-472.	0.0	4
188	KASL Clinical Practice Guidelines: Management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2012, 18, 109.	4.5	143
190	A case-control study of the relationship between hepatitis B virus DNA level and risk of hepatocellular carcinoma in Qidong, China. <i>World Journal of Gastroenterology</i> , 2008, 14, 3059.	1.4	32
191	Local recurrence of hepatocellular carcinoma after radiofrequency ablation. <i>World Journal of Gastroenterology</i> , 2010, 16, 5135.	1.4	4
192	Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2011, 17, 2945.	1.4	5
193	Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. <i>World Journal of Gastroenterology</i> , 2013, 19, 8822.	1.4	37
194	Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. <i>World Journal of Gastroenterology</i> , 2013, 19, 8887.	1.4	36
195	Management of chronic hepatitis B in severe liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 16053.	1.4	16
196	Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 8249.	1.4	24
197	Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α -2a on virological and serological responses in chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2016, 22, 10210.	1.4	12
198	Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients. <i>Saudi Journal of Gastroenterology</i> , 2015, 21, 146.	0.5	10
199	Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B. <i>World Journal of Hepatology</i> , 2010, 2, 91.	0.8	7
200	Management of chronic hepatitis B before and after liver transplantation. <i>World Journal of Hepatology</i> , 2015, 7, 1421.	0.8	17
201	Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 1742.	0.8	19
202	Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon. <i>World Journal of Hepatology</i> , 2015, 7, 2427.	0.8	14
203	Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. <i>World Journal of Hepatology</i> , 2015, 7, 825.	0.8	23
204	Quasispecies and Pre-Existing Drug-Resistant Mutations of Hepatitis B Virus in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2013, 7, 329-334.	1.4	12
205	Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy. <i>Gut and Liver</i> , 2015, 9, 395-404.	1.4	11

#	ARTICLE	IF	CITATIONS
206	Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. <i>Gut and Liver</i> , 2019, 13, 197-205.	1.4	12
207	All-atom molecular dynamics study of hepatitis B virus containing pregenome RNA in solution. <i>Journal of Chemical Physics</i> , 2021, 155, 145101.	1.2	3
208	Antiviral therapy for hepatitis B virus-associated hepatic failure. , 2009, , 164-175.		3
209	Overview of Hepatitis Viruses and Cancer. , 2012, , 509-529.		0
210	Reviews on the Epidemiology, Quality of Life, and Management of Chronic Hepatitis B (CHB). , 0, , .		0
211	Prolonged Combination Therapy is More Effective than Monotherapy in Management of Chronic Hepatitis B Patients With Sustained Virological Response: An Experience From a "Real-World" Clinical Setting. <i>Iranian Red Crescent Medical Journal</i> , 2013, 15, e7788.	0.5	2
212	Hepatitis Viruses: Hepatocellular Carcinoma. , 2014, , 785-804.		0
213	The Impact of Treating Chronic Liver Diseases on Hepatocellular Carcinoma Prevention. , 2012, , 229-246.		0
215	Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study. <i>Indian Journal of Medical Research</i> , 2016, 144, 424.	0.4	1
216	Liver Transplantation for Hepatitis B Virus-related Hepatocellular Carcinoma in Hong Kong. <i>Journal of Clinical and Translational Hepatology</i> , 2018, x, 1-6.	0.7	4
217	Entecavir Reduces Hepatocarcinogenesis in Chronic Hepatitis B Patients. <i>Acta Medica Okayama</i> , 2016, 70, 1-12.	0.1	6
218	Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. <i>Journal of Personalized Medicine</i> , 2022, 12, 149.	1.1	14
219	Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg). <i>Journal of Clinical Medicine</i> , 2022, 11, 1126.	1.0	13
222	Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B. <i>Annals of Hepatology</i> , 2017, 16, 358-365.	0.6	3
223	Total cholesterol to high-density lipoprotein ratio and nonalcoholic fatty liver disease in a population with chronic hepatitis B. <i>World Journal of Hepatology</i> , 2022, 14, 791-801.	0.8	1
224	Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 127-140.	1.0	5
225	Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. <i>Antiviral Therapy</i> , 2009, 14, 679-685.	0.6	9
226	Long-term follow-up of treatment-naïve HBeAg-negative patients with chronic hepatitis B. <i>Irish Journal of Medical Science</i> , 2023, 192, 633-639.	0.8	3

#	ARTICLE	IF	CITATIONS
227	Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir. <i>Biomedicines</i> , 2022, 10, 1637.	1.4	1
228	Measuring hepatitis B pgRNA stability using an updated automated HBV pgRNA assay with increased sensitivity. <i>Hepatology Communications</i> , 2023, 7, .	2.0	0